TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30689020

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillator (ICD) therapy
Number of subjects: 1676

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1676
Study: 28670407

Group type: EXPERIMENTAL
Intervention: Multidisciplinary group-based intervention (physiotherapy educational program + health educational program)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Multidisciplinary group-based intervention
Number of subjects: 136

Group type: COMPARATOR
Intervention: Physiotherapy educational program (control group)
Number of subjects: 136
Study: 25714044

Group type: EXPERIMENTAL
Intervention: Gardasil (qHPV) booster dose
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: Cervarix (bHPV) booster dose
Number of subjects: 366
Study: 25406682

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with house-dust mite or grass pollen; applied for 2 years after a dose-up phase.
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo; applied for 2 years after a dose-up phase.
Number of subjects: 31
Study: 22337568

Group type: EXPERIMENTAL
Intervention: Etoricoxib 120 mg preoperatively
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 19455286

Group type: EXPERIMENTAL
Intervention: Open appendectomy (OA)
Number of subjects: 130000

Group type: COMPARATOR
Intervention: Laparoscopic appendectomy (LA)
Number of subjects: 130000

Group type: EXPERIMENTAL
Intervention: Open appendectomy (OA) and Laparoscopic appendectomy (LA)
Number of subjects: 130000
Study: 17822463

Group type: EXPERIMENTAL
Intervention: Trimethoprim (200 mg)
Number of subjects: 2481

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (500 mg)
Number of subjects: 2481

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2481
Study: 14734464

Group type: EXPERIMENTAL
Intervention: Imatinib treatment (median duration of 13 months)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Genomic profile of response based on 31 identified genes
Number of subjects: 100
Study: 11964590

Group type: EXPERIMENTAL
Intervention: Morphine (0.05 mg/kg bolus + 0.2 mg/kg infusion over 40 min)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Lidocaine (1 mg/kg bolus + 4 mg/kg infusion)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Active placebo (Diphenhydramine 10 mg bolus + 40 mg infusion)
Number of subjects: 32
Study: 9579445

Group type: EXPERIMENTAL
Intervention: dl-norgestrel (0.05 mg/day)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: medroxyprogesterone acetate (2.5 mg/day)
Number of subjects: 9
Study: 7623904

Group type: EXPERIMENTAL
Intervention: Sclerotherapy with octreotide (25 micrograms per hour for five days)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Sclerotherapy alone (placebo)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Sclerotherapy with octreotide
Number of subjects: 199
Study: 2633927

Group type: EXPERIMENTAL
Intervention: Colchicine tablets (A)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Colchicine oral solution (B)
Number of subjects: 12
Study: 7377746

Group type: EXPERIMENTAL
Intervention: Sulfadiazine (SD) 4 mg/kg twice a day, loading dose 8 mg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fulfafurazole (SF) 50 mg/kg four times a day
Number of subjects: 0
Study: 30945088

Group type: EXPERIMENTAL
Intervention: Liberal fluid strategy (12 ml/kg/h)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Restricted fluid strategy (4 ml/kg/h)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Goal-directed (GD) fluid replacement using stroke volume variation (SVV)
Number of subjects: 86
Study: 31402192

Group type: EXPERIMENTAL
Intervention: Retromandibular transparotid approach
Number of subjects: 30

Group type: COMPARATOR
Intervention: Retromandibular TMAP approach
Number of subjects: 30
Study: 25829263

Group type: EXPERIMENTAL
Intervention: Educational booklet on anticoagulant treatment with warfarin
Number of subjects: 235

Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 235
Study: 23661293

Group type: EXPERIMENTAL
Intervention: Concurrent oxaliplatin 70 mg/m² weekly for six cycles
Number of subjects: 115

Group type: COMPARATOR
Intervention: Radiotherapy (RT) alone
Number of subjects: 115
Study: 17643621

Group type: EXPERIMENTAL
Intervention: Radial artery
Number of subjects: 394

Group type: COMPARATOR
Intervention: Free right internal thoracic artery
Number of subjects: 394
Study: 15242248

Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors
Number of subjects: 0
Study: 10989730

Group type: EXPERIMENTAL
Intervention: diltiazem 300 mg/daily
Number of subjects: 14

Group type: COMPARATOR
Intervention: amlodipine 10 mg/daily
Number of subjects: 14
Study: 9238883

Group type: EXPERIMENTAL
Intervention: Dentifrice containing 0.3% triclosan and 2.0% PVM/MA copolymer in a 0.243% NaF/silica (1100 ppm F) base
Number of subjects: 1542

Group type: COMPARATOR
Intervention: Dentifrice containing 0.243% NaF/silica (1100 ppm F) without triclosan and copolymer
Number of subjects: 1542
Study: 1285740

Group type: EXPERIMENTAL
Intervention: Adjuvant cisplatin-based chemotherapy (n = 97)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Chemotherapy for recurrent disease (n = 83)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Observation group (control group)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Adjuvant treatment group (control group)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Both chemotherapy groups (adjuvant and recurrent)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 180
Study: 3934402

Group type: EXPERIMENTAL
Intervention: 2.2 g protein/kg/day
Number of subjects: 21

Group type: COMPARATOR
Intervention: 1.5 g protein/kg/day
Number of subjects: 21
Study: 31133361

Group type: EXPERIMENTAL
Intervention: 10-slide PowerPoint instruction on nasal analysis
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard sequence of photographs for assessment
Number of subjects: 20
Study: 28817334

Group type: EXPERIMENTAL
Intervention: Community Health Worker (CHW) intervention
Number of subjects: 302

Group type: COMPARATOR
Intervention: Goal-setting alone (Control)
Number of subjects: 302
Study: 25798694

Group type: EXPERIMENTAL
Intervention: Er:YAG lasers
Number of subjects: 42

Group type: COMPARATOR
Intervention: Cryotherapy
Number of subjects: 42
Study: 23524720

Group type: EXPERIMENTAL
Intervention: Single peripheral nerve block using 1% lidocaine and betamethasone
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no nerve block)
Number of subjects: 60
Study: 20812862

Group type: EXPERIMENTAL
Intervention: Pentaerythritol tetranitrate (PETN) 80 mg orally two times per day for 14 days
Number of subjects: 36

Group type: COMPARATOR
Intervention: Isosorbide dinitrate (ISDN) 40 mg retarded release orally two times per day for 14 days
Number of subjects: 36
Study: 18608367

Group type: EXPERIMENTAL
Intervention: Continuous passive motion (CPM) and active exercises
Number of subjects: 63

Group type: COMPARATOR
Intervention: Active exercises only
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Whole group (both interventions)
Number of subjects: 63
Study: 16981945

Group type: EXPERIMENTAL
Intervention: Topical misoprostol
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study: 15851226

Group type: EXPERIMENTAL
Intervention: Single-3 cryothermia applications (n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Double-3 cryothermia applications (n = 20)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Single-3 cryothermia applications
Number of subjects: 40

Group type: COMPARATOR
Intervention: Double-3 cryothermia applications
Number of subjects: 40
Study: 10674537

Group type: EXPERIMENTAL
Intervention: Informational videotape (6 minutes duration)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Standard management (no videotape)
Number of subjects: 198
Study: 9100216

Group type: EXPERIMENTAL
Intervention: Pear juice (fructose in excess to glucose and a large amount of sorbitol)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Apple juice (similar to pear juice but contains four times less sorbitol)
Number of subjects: 104

Group type: COMPARATOR
Intervention: White grape juice (equal amounts of fructose and glucose, sorbitol-free)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Purple grape juice (equal amounts of fructose and glucose, sorbitol-free)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: General outcome for pear juice
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: General outcome for diarrhea
Number of subjects: 104
Study: 8463768

Group type: EXPERIMENTAL
Intervention: Regular coffee use
Number of subjects: 23

Group type: COMPARATOR
Intervention: Caffeine-free diet
Number of subjects: 23
Study: 2879782

Group type: EXPERIMENTAL
Intervention: Nizatidine 150 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nizatidine 300 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cimetidine 800 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30882670

Group type: EXPERIMENTAL
Intervention: prasugrel/ticagrelor
Number of subjects: 3985

Group type: COMPARATOR
Intervention: clopidogrel
Number of subjects: 3985
Study: 28756943

Group type: EXPERIMENTAL
Intervention: Immersive simulation of life-threatening events
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Holter analysis (heart rate and heart rate variability)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Self-reported stress
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Salivary cortisol
Number of subjects: 48
Study: 27086023

Group type: EXPERIMENTAL
Intervention: Pars plana vitrectomy with 24-gray EMB and ongoing pro re nata (PRN) ranibizumab (n = 224)
Number of subjects: 363

Group type: COMPARATOR
Intervention: Ongoing PRN ranibizumab monotherapy (n = 119)
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Pars plana vitrectomy with 24-gray EMB and ongoing PRN ranibizumab (n = 224)
Number of subjects: 363
Study: 25084784

Group type: EXPERIMENTAL
Intervention: Standard polyurethane catheter securement device
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Tissue adhesive catheter securement device
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Bordered polyurethane catheter securement device
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Sutureless securement device
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Initial design with 388 patients/arm
Number of subjects: 220
Study: 23227680

Group type: EXPERIMENTAL
Intervention: Meridian cosmetology treatment (including acupuncture at specific body acupoints and local needling therapy)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Western medication (oral administration of Vitamin C and E for 3 months)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Meridian cosmetology treatment
Number of subjects: 300
Study: 20978028

Group type: EXPERIMENTAL
Intervention: QVA149 (indacaterol/NVA237) 300/50 μg
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154

Group type: COMPARATOR
Intervention: Indacaterol 300 μg
Number of subjects: 154

Group type: COMPARATOR
Intervention: Indacaterol 600 μg
Number of subjects: 154
Study: 18617080

Group type: EXPERIMENTAL
Intervention: Behavioral intervention (20 weekly group sessions encouraging calorie restriction, moderate-intensity physical activity, and the DASH dietary pattern)
Number of subjects: 1685

Group type: EXPERIMENTAL
Intervention: Behavioral measures (diet records and physical activity)
Number of subjects: 1685

Group type: EXPERIMENTAL
Intervention: African-American men
Number of subjects: 1685

Group type: EXPERIMENTAL
Intervention: African-American women
Number of subjects: 1685

Group type: EXPERIMENTAL
Intervention: Non-African-American men
Number of subjects: 1685

Group type: EXPERIMENTAL
Intervention: Non-African-American women
Number of subjects: 1685
Study: 16037157

Group type: EXPERIMENTAL
Intervention: Narcotrend monitoring
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: BIS monitoring
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard practice
Number of subjects: 120
Study: 12783044

Group type: EXPERIMENTAL
Intervention: Exercise (EX; N = 12)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (CT; N = 12)
Number of subjects: 24
Study: 10322585

Group type: EXPERIMENTAL
Intervention: Calf-stretching exercises (4 static stretches, each lasting 30 seconds)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control condition (no calf-stretching exercises)
Number of subjects: 20
Study: 8726550

Group type: EXPERIMENTAL
Intervention: Brief standardized educational intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sexual Beliefs and Information Questionnaire (SBIQ)
Number of subjects: 0
Study: 1655219

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus involved-field radiation therapy (24 patients)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Chemotherapy alone (24 patients)
Number of subjects: 180
Study: 7052009

Group type: EXPERIMENTAL
Intervention: Phenelzine sulfate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amitriptyline hydrochloride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30725289

Group type: EXPERIMENTAL
Intervention: Magnetic steering of capsule endoscopy
Number of subjects: 227

Group type: COMPARATOR
Intervention: Standard protocol (historical control)
Number of subjects: 227
Study: 28879645

Group type: EXPERIMENTAL
Intervention: SB2 (infliximab biosimilar)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: EU-sourced Remicade (EU-IFX)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: US-sourced Remicade (US-IFX)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Subjects with ADAs vs. those without ADAs
Number of subjects: 30

Group type: COMPARATOR
Intervention: Serum infliximab at 8 weeks
Number of subjects: 30
Study: 25168346

Group type: EXPERIMENTAL
Intervention: Surgeons shown radiographs and patient information
Number of subjects: 238

Group type: COMPARATOR
Intervention: Surgeons shown radiographs alone
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Patient information (age, mechanism of injury)
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Surgeons with patient information
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Surgeons with and without patient information
Number of subjects: 238
Study: 24530144

Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Number of subjects: 120

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 120
Study: 22353006

Group type: EXPERIMENTAL
Intervention: Home Based Family Intervention (HBFI)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Enhanced Treatment as Usual (ETAU)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Both groups (HBFI and ETAU)
Number of subjects: 43
Study: 19214661

Group type: EXPERIMENTAL
Intervention: Prokinetic agent (mosapride 15 mg, orally three times daily) for 4 weeks
Number of subjects: 26

Group type: COMPARATOR
Intervention: Healthy controls (11 matched individuals)
Number of subjects: 26
Study: 17425617

Group type: EXPERIMENTAL
Intervention: Rigid backboard
Number of subjects: 23

Group type: COMPARATOR
Intervention: No backboard
Number of subjects: 23
Study: 15325893

Group type: EXPERIMENTAL
Intervention: 0.5% C31G
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1.0% C31G
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1.7% C31G
Number of subjects: 0

Group type: COMPARATOR
Intervention: Extra Strength Gynol II (N-9)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.5% C31G vs. N-9
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1.0% C31G vs. N-9
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Leakage
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acceptability
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: C31G plasma levels
Number of subjects: 0
Study: 11445849

Group type: EXPERIMENTAL
Intervention: Tegafur (FT) alone or FT plus low doses of cisplatin
Number of subjects: 71
Study: 11360524

Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate (BDP) 1000 micrograms daily for 6 weeks
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 8198943

Group type: EXPERIMENTAL
Intervention: Steady exercise for 8 min
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: FEV1 measurements
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Exercise plus FEV1 measurements
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (no manoeuvre)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Valsalva manoeuvres
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Hyperventilation for 3 min
Number of subjects: 8
Study: 3045746

Group type: EXPERIMENTAL
Intervention: Cimetidine (1 g daily, 3 tablets during the day and 2 tablets at night)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Cimetidine (1 g daily)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Cimetidine-Placebo
Number of subjects: 37
Study: 30747267

Group type: EXPERIMENTAL
Intervention: Beetroot juice (BRJ) supplementation (8.4 mmol NO3‐ day‐ 1)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (PLA) (0.01 mmol NO3‐ day‐ 1)
Number of subjects: 13
Study: 28259304

Group type: EXPERIMENTAL
Intervention: Excessive alcohol ingestion
Number of subjects: 199
Study: 26394270

Group type: EXPERIMENTAL
Intervention: Glatiramer acetate 40 mg/mL three times weekly subcutaneous injection (GA40)
Number of subjects: 1404

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1404
Study: 23385649

Group type: EXPERIMENTAL
Intervention: Acute Slow Breathing (SLOWB)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Long-term Slow Breathing (SLOWB)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (matched hypertensive controls)
Number of subjects: 10
Study: 21559038

Group type: EXPERIMENTAL
Intervention: 10 g/d BSP (n=21)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: 5 g/d BSP (n=22)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo (n=20)
Number of subjects: 81
Study: 17964616

Group type: EXPERIMENTAL
Intervention: Whey protein preload (300 mL, 1 MJ)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control preload (low protein)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: GMP preload (GMP isolate)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Whey (‐)GMP preload (whey protein without GMP)
Number of subjects: 20
Study: 16767021

Group type: EXPERIMENTAL
Intervention: Mechanical ventilation with limited tidal volume size and respiratory rate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Use of positive end expiratory pressure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Application of helium‐oxygen mixtures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Specific inspiratory and expiratory ratios
Number of subjects: 0
Study: 14668455

Group type: EXPERIMENTAL
Intervention: Three-drug regimen containing efavirenz combined with zidovudine and lamivudine
Number of subjects: 620

Group type: EXPERIMENTAL
Intervention: Zidovudine and lamivudine combined with efavirenz
Number of subjects: 620

Group type: EXPERIMENTAL
Intervention: Initial use of zidovudine, lamivudine, and efavirenz
Number of subjects: 620
Study: 10710885

Group type: EXPERIMENTAL
Intervention: Intraglobin (400 mg/kg/d x 5)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Venoglobulin-I (1 g/kg/d x 2)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Venoglobulin-I
Number of subjects: 17
Study: 8726950

Group type: EXPERIMENTAL
Intervention: Inhaled glucocorticosteroids (standard pediatric doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inhaled glucocorticosteroids
Number of subjects: 0
Study: 1340901

Group type: EXPERIMENTAL
Intervention: Subcutaneous Continuous Preprogrammed Insulin Infusion (SCII)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Multiple Conventional Insulin Injections (MCII)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both SCII and MCII
Number of subjects: 28
Study: 6502211

Group type: EXPERIMENTAL
Intervention: Naloxone (2 mg, i.v.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3959854

Group type: EXPERIMENTAL
Intervention: NaHCO3
Number of subjects: 10

Group type: COMPARATOR
Intervention: CaCO3
Number of subjects: 10
Study: 29890270

Group type: EXPERIMENTAL
Intervention: MCC (60 mL·d‐1)
Number of subjects: 16

Group type: COMPARATOR
Intervention: PLA (placebo)
Number of subjects: 16
Study: 27401352

Group type: EXPERIMENTAL
Intervention: Bevel-down group
Number of subjects: 204

Group type: COMPARATOR
Intervention: Bevel-up group
Number of subjects: 204
Study: 25333925

Group type: EXPERIMENTAL
Intervention: Olfactory ensheathing cells (OECs) intraspinal transplantation
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Schwann cells (SCs) implantation
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Combination of OECs and SCs
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 28
Study: 23341314

Group type: EXPERIMENTAL
Intervention: Playing the video game Dr. Kawashima's Brain Training: How Old Is Your Brain?
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (did not play the video game)
Number of subjects: 32
Study: 19889796

Group type: EXPERIMENTAL
Intervention: Ketoconazole (200 mg b.i.d.)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Fluconazole (400 mg once a day)
Number of subjects: 20
Study: 18074365

Group type: EXPERIMENTAL
Intervention: AV cued task-specific training
Number of subjects: 52

Group type: COMPARATOR
Intervention: Conventional exercise (Ex)
Number of subjects: 52
Study: 16437366

Group type: EXPERIMENTAL
Intervention: Intraoperative peritoneal hyperthermic chemotherapy (IPHC)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Control (no IPHC)
Number of subjects: 118
Study: 12839854

Group type: EXPERIMENTAL
Intervention: Sentinel node biopsy
Number of subjects: 250
Study: 10384736

Group type: EXPERIMENTAL
Intervention: Understanding of materials requiring attribution of mental states (e.g. ignorance, false belief)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy elderly subjects and a small group of left hemisphere patients (who received the tasks in modified form)
Number of subjects: 0
Study: 8887137

Group type: EXPERIMENTAL
Intervention: GH/hMG/hCG
Number of subjects: 42

Group type: COMPARATOR
Intervention: hMG/hCG
Number of subjects: 42
Study: 1648488

Group type: EXPERIMENTAL
Intervention: 4 mg molsidomine
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 20 mg isosorbide-5-mononitrate (ISMN)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11